Apricus Biosciences Announces Sale of Ex-U.S. Vitaros Assets and Rights to Ferring Pharmaceuticals
March 08, 2017 16:01 ET
|
Apricus Biosciences
Apricus Expects to Receive Approximately $12.7 Million from Ferring Apricus to Focus on Vitaros U.S. NDA Re-Submission and Pipeline Assets Post-ClosingSAN DIEGO, March 08, 2017 (GLOBE NEWSWIRE) --...
Apricus Biosciences Announces Approval of Vitaros® for the Treatment of Erectile Dysfunction in Mexico
January 18, 2017 07:00 ET
|
Apricus Biosciences
SAN DIEGO, Jan. 18, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that...
Apricus Biosciences Announces the Launch of Vitaros® for the Treatment of Erectile Dysfunction in Lebanon by Elis Pharmaceuticals
December 27, 2016 07:00 ET
|
Apricus Biosciences
SAN DIEGO, Dec. 27, 2016 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced the...
Apricus Biosciences Announces Approval of Vitaros® for the Treatment of Erectile Dysfunction in Greece
October 26, 2016 07:00 ET
|
Apricus Biosciences
SAN DIEGO, Oct. 26, 2016 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that...
Apricus Biosciences Announces the Launch of Vitaros® in the Czech Republic and Slovakia by Recordati
September 21, 2016 07:00 ET
|
Apricus Biosciences
SAN DIEGO, Sept. 21, 2016 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced the...
Apricus Biosciences Announces Approval of Vitaros® for the Treatment of Erectile Dysfunction in Argentina
September 08, 2016 07:00 ET
|
Apricus Biosciences
SAN DIEGO, Sept. 08, 2016 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that...
Apricus Biosciences Announces the Launch of Its Novel Topical Treatment for Erectile Dysfunction in Portugal, Ireland and Poland by Recordati
September 06, 2016 07:00 ET
|
Apricus Biosciences
SAN DIEGO, Sept. 06, 2016 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced the...
Apricus Biosciences Further Expands Existing Vitaros® Partnership with Ferring Pharmaceuticals in Europe and Asia
July 25, 2016 07:00 ET
|
Apricus Biosciences
Apricus Eligible to Receive an Additional $3.6 Million in Upfront and Pre-Commercialization Milestone Payments for the Expanded Territory Apricus and Sandoz Agree to Mutually Terminate...
Apricus Biosciences to File for Market Authorization to Sell Vitaros(R) for Erectile Dysfunction in Latin America
August 08, 2011 10:03 ET
|
Seelos Therapeutics, Inc.
SAN DIEGO, Aug. 8, 2011 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio") (Nasdaq:APRI) announced today that it will file for market authorization to sell its erectile dysfunction drug,...